Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2014-06-24

Clinical Trial Update: Safety and Tolerability of Dalfampridine in Subjects With Cerebral Palsy [Phase 1]

View source ↗

Summary

Phase 1 study update reporting on the safety and tolerability of dalfampridine in subjects with cerebral palsy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Dalfampridine (dalfampridine)

Snippet

Sponsor: Acorda Therapeutics | Conditions: Cerebral Palsy (CP) | Phase 1 | Status: COMPLETED | Results posted: 2014-06-24